Solvias is expanding its global network of laboratory testing centers with a new biotech site in Research Triangle Park, N.C.
KAISERAUGST, Switzerland, Jan. 23, 2024 /PRNewswire/ -- Solvias, a global provider of chemistry, manufacturing, and control (CMC) analytics, announced today that it will perform analytical release testing services on the world's first CRISPR/Cas9 genome-edited cell therapy. The company has signed a long-term agreement with Vertex Pharmaceuticals for CASGEVY™ (exagamglogene autotemcel or exa-cel) which received U.S. Food & Drug Administration (FDA) approval for the treatment of sickle cell disease (SCD) in patients 12 years and older with recurrent vaso-occlusive crises.
Solvias, one of the world's leading independent pharmaceutical testing and manufacturing companies, announced today that it has acquired Utrecht,...
KAISERAUGST, Switzerland, March 8, 2022 /PRNewswire/ -- Solvias, one of the largest independent analytical testing, contract research, development and manufacturing companies, today announced that its board of directors has appointed Archie Cullen chief executive officer. Highly regarded for his 20-year track record of growing global life sciences businesses, Mr. Cullen will spearhead Solvias' strategic expansion.
Establishes U.S. lab presence and expands testing services.
KAISERAUGST, Switzerland, June 17, 2021 /PRNewswire/ -- Solvias, one of the largest independent analytical testing, contract research, development and manufacturing companies, today announced that it has acquired Canton, Mass.-based Chemic Laboratories, Inc. (Chemic). With this acquisition, Solvias gains a strong foothold in the United States and highly complementary laboratory testing capabilities.
Bachem (SIX: BANB) today announced that Stephan Schindler, CFO of the Bachem Group since 2009 and member of the Corporate Executive Committee, has decided to continue his career outside the company as of the end of March 2021. He will be succeeded as CFO effective February 1, 2021 by Alain Schaffter, currently CFO a.i. at Solvias AG in Kaiseraugst. He will report to CEO Thomas Meier and become a member of the Corporate Executive Committee.
KAISERAUGST, Switzerland, June 11, 2020 /PRNewswire/ -- Solvias, a world leader in contract research, development and manufacturing, today announced that it has completed an agreement with strategic health care investors, Water Street Healthcare Partners and JLL Partners, to fully acquire and invest in growing Solvias. The agreement is the next step in Solvias' expansion focused on building the company into a global leader of high-quality pharmaceutical laboratory services.
Water Street Healthcare Partners, a strategic investor focused exclusively on the health care industry, announced today that it has signed a definitive agreement to invest in Solvias AG. Headquartered in the biotech hub of Basel, Switzerland, Solvias is one of the largest independent pharmaceutical laboratory platforms in Europe. Water Street, which has years of experience in the pharmaceutical services sector, will partner with the company's management team to build Solvias into a premier global pharmaceutical laboratory services business.
Merck, a leading science and technology company, today announced a collaboration with Solvias, a Swiss contract research and service provider, to offer the PyroMAT™ System, a new MAT kit for pyrogen detection. The kit, which joins other products in Merck’s Pyrogen Detection portfolio, was developed collaboratively by both companies.